FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2045940197> ?p ?o ?g. }

• W2045940197 endingPage "2780" @default.
• W2045940197 startingPage "2773" @default.
• W2045940197 abstract "Abstract A previous study (LMB89) of the French Society of Pediatric Oncology for childhood mature B-cell lymphoma (B-NHL) demonstrated a 92% 3-year event-free survival (EFS) for intermediate-risk group B defined as “non-resected” stage I/II and CNS-negative advanced-stage III/IV (70% of cases). We performed the FAB/LMB96 trial to assess the possibility of reducing treatment in children/adolescents with intermediate-risk B-NHL without jeopardizing survival. “Early responding” patients (tumor response > 20% at day 7) were randomized in a factorial design between 4 arms, 2 receiving half-dose of cyclophosphamide in the second induction course with cyclophosphamide, Oncovin (vincristine), prednisone, Adriamycin (doxorubicin), methotrexate (COPADM) and 2 not receiving the maintenance course M1. A total of 657 patients were randomized (May 1996 to June 2001) and 637 were analyzed. The analysis showed no significant effect of any of the treatment reductions on EFS and survival. The 4-year EFS was 93.4% and 90.9% in the groups with full-dose and half-dose of cyclophosphamide (RR = 1.3, P = .40) and 91.9% and 92.5% in the groups with and without M1 (RR = 1.01, P = .98). There was no interaction between the 2 treatment reductions or between each treatment reduction and LDH level or histologic subtypes (Burkitt/Burkitt-like or large B-cell). Children/adolescents with intermediate-risk B-NHL who have an early response and achieve a complete remission after the first consolidation course can be cured with a 4-course treatment with a total dose of only 3.3 g/m2 cyclophosphamide and 120 mg/m2 doxorubicin." @default.
• W2045940197 created "2016-06-24" @default.
• W2045940197 creator A5001697191 @default.
• W2045940197 creator A5017985440 @default.
• W2045940197 creator A5024265201 @default.
• W2045940197 creator A5027448217 @default.
• W2045940197 creator A5041052627 @default.
• W2045940197 creator A5047701227 @default.
• W2045940197 creator A5047962328 @default.
• W2045940197 creator A5064356559 @default.
• W2045940197 creator A5079829314 @default.
• W2045940197 creator A5080068885 @default.
• W2045940197 creator A5081742161 @default.
• W2045940197 date "2006-11-28" @default.
• W2045940197 modified "2023-10-18" @default.
• W2045940197 title "Results of the randomized international FAB/LMB96 trial for intermediate risk B-cell non-Hodgkin lymphoma in children and adolescents: it is possible to reduce treatment for the early responding patients" @default.
• W2045940197 cites W1672417844 @default.
• W2045940197 cites W1775087301 @default.
• W2045940197 cites W1814753114 @default.
• W2045940197 cites W1862618844 @default.
• W2045940197 cites W1864995945 @default.
• W2045940197 cites W1889566095 @default.
• W2045940197 cites W1984151990 @default.
• W2045940197 cites W1995787475 @default.
• W2045940197 cites W2013579108 @default.
• W2045940197 cites W2013692191 @default.
• W2045940197 cites W2019063768 @default.
• W2045940197 cites W2026984405 @default.
• W2045940197 cites W2038580248 @default.
• W2045940197 cites W2040711350 @default.
• W2045940197 cites W2042216531 @default.
• W2045940197 cites W2055502243 @default.
• W2045940197 cites W2072309876 @default.
• W2045940197 cites W2098871445 @default.
• W2045940197 cites W2105709049 @default.
• W2045940197 cites W2156073127 @default.
• W2045940197 cites W2159263318 @default.
• W2045940197 cites W2163570758 @default.
• W2045940197 cites W2317101636 @default.
• W2045940197 doi "https://doi.org/10.1182/blood-2006-07-036673" @default.
• W2045940197 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/1852229" @default.
• W2045940197 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17132719" @default.
• W2045940197 hasPublicationYear "2006" @default.
• W2045940197 type Work @default.
• W2045940197 sameAs 2045940197 @default.
• W2045940197 citedByCount "369" @default.
• W2045940197 countsByYear W20459401972012 @default.
• W2045940197 countsByYear W20459401972013 @default.
• W2045940197 countsByYear W20459401972014 @default.
• W2045940197 countsByYear W20459401972015 @default.
• W2045940197 countsByYear W20459401972016 @default.
• W2045940197 countsByYear W20459401972017 @default.
• W2045940197 countsByYear W20459401972018 @default.
• W2045940197 countsByYear W20459401972019 @default.
• W2045940197 countsByYear W20459401972020 @default.
• W2045940197 countsByYear W20459401972021 @default.
• W2045940197 countsByYear W20459401972022 @default.
• W2045940197 countsByYear W20459401972023 @default.
• W2045940197 crossrefType "journal-article" @default.
• W2045940197 hasAuthorship W2045940197A5001697191 @default.
• W2045940197 hasAuthorship W2045940197A5017985440 @default.
• W2045940197 hasAuthorship W2045940197A5024265201 @default.
• W2045940197 hasAuthorship W2045940197A5027448217 @default.
• W2045940197 hasAuthorship W2045940197A5041052627 @default.
• W2045940197 hasAuthorship W2045940197A5047701227 @default.
• W2045940197 hasAuthorship W2045940197A5047962328 @default.
• W2045940197 hasAuthorship W2045940197A5064356559 @default.
• W2045940197 hasAuthorship W2045940197A5079829314 @default.
• W2045940197 hasAuthorship W2045940197A5080068885 @default.
• W2045940197 hasAuthorship W2045940197A5081742161 @default.
• W2045940197 hasBestOaLocation W20459401971 @default.
• W2045940197 hasConcept C126322002 @default.
• W2045940197 hasConcept C143998085 @default.
• W2045940197 hasConcept C146357865 @default.
• W2045940197 hasConcept C151730666 @default.
• W2045940197 hasConcept C168563851 @default.
• W2045940197 hasConcept C2776694085 @default.
• W2045940197 hasConcept C2776755627 @default.
• W2045940197 hasConcept C2778720950 @default.
• W2045940197 hasConcept C2779338263 @default.
• W2045940197 hasConcept C2779429289 @default.
• W2045940197 hasConcept C2781059491 @default.
• W2045940197 hasConcept C71924100 @default.
• W2045940197 hasConcept C86803240 @default.
• W2045940197 hasConcept C90924648 @default.
• W2045940197 hasConceptScore W2045940197C126322002 @default.
• W2045940197 hasConceptScore W2045940197C143998085 @default.
• W2045940197 hasConceptScore W2045940197C146357865 @default.
• W2045940197 hasConceptScore W2045940197C151730666 @default.
• W2045940197 hasConceptScore W2045940197C168563851 @default.
• W2045940197 hasConceptScore W2045940197C2776694085 @default.
• W2045940197 hasConceptScore W2045940197C2776755627 @default.
• W2045940197 hasConceptScore W2045940197C2778720950 @default.
• W2045940197 hasConceptScore W2045940197C2779338263 @default.
• W2045940197 hasConceptScore W2045940197C2779429289 @default.
• W2045940197 hasConceptScore W2045940197C2781059491 @default.
• W2045940197 hasConceptScore W2045940197C71924100 @default.
• W2045940197 hasConceptScore W2045940197C86803240 @default.

• next